New induction and postinduction strategies in acute myeloid leukemiaBurnett, Alan K.Current Opinion in Hematology: March 2012 - Volume 19 - Issue 2 - p 76–81 doi: 10.1097/MOH.0b013e3283500a92 MYELOID DISEASE: Edited by Martin S. Tallman Abstract Author Information Purpose of review Improving or replacing the traditional induction (3 + 7) and consolidation (high-dose cytarabine; Ara-C) as the standard of care for acute myeloid leukemia (AML) has proved disappointing. Recent findings Recent studies have raised the possibility that daunorubicin dose escalation might have the potential to improve survival. Antibody-directed therapy by means of gemtuzumab ozogamicin as an adjunct to induction chemotherapy may yet be a viable option in older patients, and alternative nucleoside analogues in induction could help higher risk subgroups. In consolidation, the number of courses and dose level of Ara-C required are being clarified. New treatments for older patients who will not be subjected to conventional chemotherapy are an active area, but randomized trials have not yet usurped low-dose Ara-C (LDAC). Summary Recent information in these areas is reviewed. Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK Correspondence to Alan K. Burnett, Department of Haematology, School of Medicine, Cardiff University, Heath Park, Cardiff CF4 14XN, UK. Tel: +44 2920742375; fax: +44 2920744655; e-mail: BurnettAK@Cardiff.ac.uk © 2012 Lippincott Williams & Wilkins, Inc.